TY - JOUR
T1 - New oral drugs in older patients
T2 - A review of idarubicin in elderly patients
AU - Crivellari, Diana
AU - Lombardi, Davide
AU - Spazzapan, Simon
AU - Veronesi, Andrea
AU - Toffoli, Giuseppe
PY - 2004/2
Y1 - 2004/2
N2 - Idarubicin (IDA) is a structural analogue of daunorubicin with the same mechanism of action. Unlike the other currently available anthracyclines, it has a significant oral bioavailability, which makes it particularly attractive for the treatment of elderly patients. IDA resulted at least as effective as daunorubicin for acute nonlymphocytic leukemia and additional data are in analysis as far as lymphomas and breast cancer are concerned. Adverse effects are mainly hematological, while hair loss, mucositis and cardiotoxicity are less frequently reported with IDA than with other anthracyclines. The pharmacokinetics, activity, adverse effects and new modalities of oral administration are reviewed.
AB - Idarubicin (IDA) is a structural analogue of daunorubicin with the same mechanism of action. Unlike the other currently available anthracyclines, it has a significant oral bioavailability, which makes it particularly attractive for the treatment of elderly patients. IDA resulted at least as effective as daunorubicin for acute nonlymphocytic leukemia and additional data are in analysis as far as lymphomas and breast cancer are concerned. Adverse effects are mainly hematological, while hair loss, mucositis and cardiotoxicity are less frequently reported with IDA than with other anthracyclines. The pharmacokinetics, activity, adverse effects and new modalities of oral administration are reviewed.
KW - Elderly breast cancer patients
KW - Oral anthracyclines
KW - Oral idarubicin
UR - http://www.scopus.com/inward/record.url?scp=0842285393&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0842285393&partnerID=8YFLogxK
U2 - 10.1016/S1040-8428(03)00120-3
DO - 10.1016/S1040-8428(03)00120-3
M3 - Article
C2 - 15012975
AN - SCOPUS:0842285393
VL - 49
SP - 153
EP - 163
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
SN - 1040-8428
IS - 2
ER -